Latest Breaking News On - Keynote 859 trial - Page 1 : comparemela.com

The European Commission has approved new indications for pembrolizumab in combination with chemotherapy in select patients with gastric or gastroesophageal adenocarcinoma and select patients with biliary tract cancer.

European unionEuropean commissionMerck research laboratoriesEligibility criteriaGastric cancerGastroesophageal cancerBiliary tract carcinomaGi cancersGastrointestinal cancersKeynote 859 trialKeynote 966 trial